People with BRCA1 mutations have a higher risk of developing cancer, which warrants accurate evaluation of the function of BRCA1 variants. Herein, we described a protocol for functional assessment of BRCA1 variants using CRISPR-mediated cytosine base editors that enable targeted C:G to T:A conversion in living cells.
Recent studies have investigated the risks associated with BRCA1 gene mutations using various functional assessment methods such as fluorescent reporter assays, embryonic stem cell viability assays, and therapeutic drug-based sensitivity assays. Although they have clarified a lot of BRCA1 variants, these assays involving the use of exogenously expressed BRCA1 variants are associated with overexpression issues and cannot be applied to post-transcriptional regulation. To resolve these limitations, we previously reported a method for functional analysis of BRCA1 variants via CRISPR-mediated cytosine base editor that induce targeted nucleotide substitution in living cells. Using this method, we identified variants whose functions remain ambiguous, including c.-97C>T, c.154C>T, c.3847C>T, c.5056C>T, and c.4986+5G>A, and confirmed that CRISPR-mediated base editors are useful tools for reclassifying the variants of uncertain significance in BRCA1. Here, we describe a protocol for functional analysis of BRCA1 variants using CRISPR-based cytosine base editor. This protocol provides guidelines for the selection of target sites, functional analysis and evaluation of BRCA1 variants.
The breast cancer type 1 susceptibility gene (BRCA1) is a widely known tumor suppressor gene. Because the BRCA1 gene is related to the repair of DNA damage, mutations in this gene would lead to a greater risk of cancer development in an individual1. Breast, ovarian, prostate, and pancreatic cancers are linked to inherited loss-of-function (LOF) mutations of the BRCA1 gene2. Functional assessment and identification of BRCA1 variants may help in preventing and diagnosing the various diseases. To address function of BRCA1 variants, several methods have been developed and broadly used for investigating the pathogenicity of BRCA1 variants such as embryonic stem cell viability assays, fluorescent reporter assays, and therapeutic drug-based sensitivity assays3,4,5,6. Although these methods have assessed the function of a lot of BRCA1 variants, the methods involving exogenously expressed BRCA1 variants pose limitations in terms of overexpression that might affecting downstream regulation, gene dosage, and protein folding7. Furthermore, these assays cannot be harnessed to the posttranscriptional regulation such as mRNA splicing, transcript stability, and effect of untranslated region8,9.
CRISPR-Cas9 system enables targeted genome editing in living cells and organisms10. Through a single-guide RNA, Cas9 can induce double-strand breaks (DSBs) in chromosomal DNA at specific genomic loci in order to activate two DNA repair pathways: error-prone nonhomologous end-joining (NHEJ) pathway and error-free homology-directed repair (HDR) pathway11. HDR is a precise repair mechanism; however, DSBs induced by Cas9 nuclease for HDR often results in unwanted insertion and deletion (indel) mutation. Additionally, it needs homologous donor DNA templates for repairing DNA damage and has relatively low efficiency. Recently, Cas9 nickase (nCas9) have been fused with cytidine deaminase domains for targeting C:G to T:A substitutions, without the need for homologous DNA templates and DNA double strand breaks12,13,14,15. Using the cytosine base editor, we developed a new method for functional analysis of BRCA1 variants16.
In this study, we used CRISPR-mediated cytosine base editor, BE314, which induces efficient C:G to T:A point mutations, for implementing the functional assessment of BRCA1 variants and successfully identified the functions of several BRCA1 variants (Figure 1).
Figure 1: An overview of the workflow for functional assessment. (A) Schematic showing the functional assessment of BRCA1. Because the LOF of BRCA1 affects cell viability, when the BRCA1 mutation is pathogenic, the cells die as the passage number increases. (B) Stages of the functional assessment of BRCA1. Dotted box is optional. It can be replaced by co-transfection of gRNA expressing and BE3 expressing plasmids DNA. Please click here to view a larger version of this figure.
NOTE: Method 1 (generation of HAP1-BE3 cell lines) is optional. Instead of constructing a BE3-expressing cell line, BE3-encoding plasmid DNA can be co-transfected with gRNA-encoding plasmid DNA. Other variants of cytosine base editors, such as BE4max, also can be used for highly efficient base editing.
1. Generation of HAP1-BE3 cell lines
2. Design and construction of BRCA1 targeting gRNAs
Figure 2: An example of a gRNA plasmid DNA. (A) To effectively edit the target sequence with BE3, an NGG PAM (CCN PAM) that places the target C (target G) within a five-nucleotide window is required. NGG PAM is shown in red and the base editing window is represented by a gray box. (B) The gRNA sequence for c.8047C>T (H1283Y) base editing is indicated and the target C:G pairs are shown in red while the active window is highlighted by a gray box. For gRNA cloning, the overhang sequences indicated in bold are added at both the 5ʹ ends. Templates for gRNA were generated by annealing the two complementary oligonucleotides. Please click here to view a larger version of this figure.
NOTE: Positive and negative controls of BRCA1 variants are essential. In this study, c.5252G>A (R1751Q) and c.4527C>T (Y1509Y) are used as benign controls. c.191G>A (C64Y), 81-1G>A, and c.3598C>T (Q1200*) are used as pathogenic controls. Target sequences of each gRNA are listed in Supplementary Table 1.
3. Creation of BRCA1 variants using CRISPR-mediated base editing tools
NOTE: If HAP1-BE3 cell lines is not used, BE3-encoding plasmid DNA can be co-transfected with BRCA1-targeting gRNA. Compared to co-transfection of BE3 and gRNA plasmids, transfection of gRNA plasmid to HAP-BE3 cells induce efficient base editing up to 3-fold at target locus in our hands.
4. Sample preparation for Illumina next-generation sequencing (NGS)
Figure 3: Preparation for next-generation sequencing. The 1st PCR primer was designed to amplify the BRCA1 target site on genomic DNA. The 2nd PCR primer was designed such that its sequences are located more inside than the 1st PCR primer sequences. Additional sequences shown as a yellow bar were added at both ends of the 2nd PCR primer to attach the essential sequences for performing next-generation sequencing. Please click here to view a larger version of this figure.
5. Analysis of base editing efficiency for the functional assessment of BRCA1 variants
The experimental approaches described in this protocol enable the functional assessment of endogenous BRCA1 variants generated by CRISPR-based cytosine base editors. To select appropriate cell lines for the functional assessment of BRCA1 variants, researchers should confirm that BRCA1 is essential gene in the targeted cell lines. For example, we first transfected Cas9 and gRNAs into HAP1 cell lines to disrupt BRCA1 and analyzed mutation frequencies by targeted deep sequencing. We found that mutation frequencies decreased significantly over time in HAP1 cell lines (Figure 4A). These results showed that BRCA1 is essential gene for cell viability in HAP1 cell lines. To investigate whether C:G to T:A substituted variants affect the function of BRCA1, the plasmids DNA encoding gRNAs, which could induce each mutation, were transfected to HAP1-BE3 cell lines and the substitution frequencies were analyzed. The relative substitution frequencies of c.3598C>T (p. Q1200*), a pathogenic variant, dramatically decreased, whereas those of c.4527C>T (p.Y1509Y), a benign variant, remained similar with time (Figure 4B). In the ClinVar database, c.154C>T (p. L52F), c.3847C>T (p.H1283Y), and c.5056C>T (p.H1686Y) of BRCA1 are reported as variants of uncertain significance. We analyzed function of these variants using the methods mentioned above and found that nucleotide substitution frequencies of these three variants decreased in a time-dependent manner (Figure 4B). From these results, the three substitutions altered BRCA1 function and could be categorized as pathogenic mutations.
Figure 4: Representative results of functional study of BRCA1 using CRISPR-Cas9 systems. (A) BRCA1 disruption affects to the cell viability. HAP1 cells were transfected with plasmid encoding spCas9 and two gRNAs targeting BRCA1, respectively, and targeted deep sequencing was performed for cell viability analysis. Mutation frequencies of BRCA1 decreased in a time-dependent manner in cells transfected with two independent gRNAs, and the mutation frequencies of CCR5, which was used as a negative control, remained the same over time. (B) Functional assessments of five BRCA1 variants. HAP1-BE3 cells were transfected with gRNAs inducing BRCA1 mutations, respectively, and targeted deep sequencing was performed for cell viability analysis. The relative substitution frequencies decreased in a time-dependent manner in cells of c.3598C>T, c.154C>T, c.3847C>T, and c.5056C>T and those of c.4527C>T remained the same. Error bars show the standard error of mean. Asterisks denote different P values: * P<0.05; ** P<0.005., n.s: not significant. Please click here to view a larger version of this figure.
This protocol describes a simple method for functional assessments of BRCA1 variants using CRISPR-meditated cytosine base editor. The protocol describes methods for the design of gRNAs at target locus and construction of the plasmid DNAs from which they are expressed. Cytosine base editors induce nucleotide conversion in an active window (in case of BE3, nucleotides 4–8 in the PAM-distal end of the gRNA target sequences). The researcher should carefully choose target sequences because all cytosines in active window can be substituted to thymines. Furthermore, as described in Step 5, multiple cytosines in an active window should be carefully analyzed to evaluate the function of BRCA1 variants.
One of the most important steps is transfection in the target cell line, which affects the initial mutation frequency for BRCA1 functional assessments. To improve the initial mutation frequency, the researchers should optimize the delivery methods to the cell line of interest. As described in Step 1, the generation of BE3 expressing cell lines is useful option to increase the initial mutation frequency. We do not recommend lentiviral transduction of gRNA into the HAP1-BE3 cells, because constitutive expression of BE3 and gRNA could cause accumulative nucleotide conversion, and these results interfere with the functional assessment of BRCA1 variants.
In addition to the BE3 mediated methods introduced in this protocol, several complementary methods are recommended to further extend the functional assessments of BRCA1 variants. First, as described above, the mutation frequency in the initial sample is important in order to obtain confident results of BRCA1 variants. To increase the base editing efficiency, variants of cytosine base editors, such as BE4max, are recommended. Second, the BE3 recognize target DNA sequence through the 5’-NGG-3’ PAM sequences, which is a limitation in generating various types of BRCA1 variants. Recently developed Cas9 variants with altered PAM sequences are useful option in this case to extend targetable BRCA1 variants26,27,28. Third, the BE3 induces substantial base editing at unwanted sites and the off-target effect could influence functional assessment of BRCA1 variants29,30,31. To reduce the off-target effect of BE3, target sites of gRNAs should be carefully chosen without any similar sequences in the genome. SECURE-BE3 or YE1, which has developed for reducing unwanted base editing in genome and transcriptome are useful option32,33. Forth, a saturation genome editing (SGE) method based on Cas9-mediated HDR also great options for functional analysis of BRCA1 variants19. The method has no limitation for selecting target sequences and nucleotide positions of BRCA1 variants. However, HDR-based approach is relatively less efficient than the base editors and additionally requires design and synthesis of donor templates14. Finally, patient derived BRCA1 variants include various range of mutations such as point mutations, insertions, and deletions. Of these, point mutations are major population of BRCA1 variants, which are not only C:G to T:A conversion, but also A:T to G:C, C:G to G:C, and A:T to T:A conversions. To functional assessments of these types of conversions, CRISPR-mediated adenosine base editors and Prime Editors are valuable options34,35. Rapidly developing genome engineering technologies will enable functional assessments of more diverse BRCA1 variants.
The authors have nothing to disclose.
This work was supported by the National Research Foundation of Korea (grants 2017M3A9B4062419, 2019R1F1A1057637, and 2018R1A5A2020732 to Y.K.).
BamHI | NEB | R3136 | Restriction enzyme |
Blasticidin | Thermo Fisher Scientific | A1113903 | Drug for selecting transduced cells |
BsaI | NEB | R0535 | Restriction enzyme |
DNeasy Blood & Tissue Kit | Qiagen | 69504 | Genomic DNA prep. kit |
Dulbecco’s modified Eagle’s medium | Gibco | 11965092 | Medium for HEK293T/17 cells |
Fetal bovine serum | Gibco | 16000036 | Supplemetal for cell culture |
FuGENE HD Transfection Reagent | Promega | E2311 | Transfection reagent |
Gibson Assembly Master Mix | NEB | E2611L | Gibson assembly kit |
Iscove’s modified Dulbecco’s medium | Gibco | 12440046 | Medium for HAP1 cells |
lentiCas9-Blast | Addgene | 52962 | Plasmids DNA for lentiBE3 cloning |
Lipofectamine 2000 | Thermo Fisher Scientific | 11668027 | Transfection reagent |
Opti-MEM | Gibco | 31985070 | Transfection materials |
pCMV-BE3 | Addgene | 73021 | Plasmids DNA for lentiBE3 cloning |
Penicillin-Streptomycin | Gibco | 15140 | Supplemetal for cell culture |
Phusion High-Fidelity DNA Polymerase | NEB | M0530SQ | High-fidelity polymerase |
pMD2.G | Addgene | 12259 | Plasmids DNA for virus prep. |
pRG2 | Addgene | 104174 | gRNA cloning vector |
psPAX2 | Addgene | 12260 | Plasmids DNA for virus prep. |
QIAprep Spin Miniprep kit | Qiagen | 27106 | Plasmid DNA prep. Kit |
QIAquick Gel extraction Kit | Qiagen | 28704 | Gel extraction kit |
QIAquick PCR Purification Kit | Qiagen | 28104 | PCR product prep. kit |
Quick Ligation Kit | NEB | M2200 | Ligase for gRNA cloning |
T7 Endonuclease I | NEB | M0302 | Materials for T7E1 assay |
XbaI | NEB | R0145 | Restriction enzyme |